CA3237744A1 - Inhibiteurs de l'usp9x - Google Patents

Inhibiteurs de l'usp9x

Info

Publication number
CA3237744A1
CA3237744A1 CA3237744A CA3237744A CA3237744A1 CA 3237744 A1 CA3237744 A1 CA 3237744A1 CA 3237744 A CA3237744 A CA 3237744A CA 3237744 A CA3237744 A CA 3237744A CA 3237744 A1 CA3237744 A1 CA 3237744A1
Authority
CA
Canada
Prior art keywords
compound
substituted
usp9x
cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3237744A
Other languages
English (en)
Inventor
Richard Martinelli
Julian F. Bond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prodeg LLC
Original Assignee
Prodeg LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prodeg LLC filed Critical Prodeg LLC
Priority claimed from PCT/US2022/050069 external-priority patent/WO2023091464A1/fr
Publication of CA3237744A1 publication Critical patent/CA3237744A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés qui inhibent les DUB, en particulier l'USP9X. L'invention concerne également des procédés d'inhibition des DUB, y compris de l'USP9X, et des méthodes de traitement de cancers.
CA3237744A 2021-11-16 2022-11-16 Inhibiteurs de l'usp9x Pending CA3237744A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163279783P 2021-11-16 2021-11-16
US63/279,783 2021-11-16
PCT/US2022/050069 WO2023091464A1 (fr) 2021-11-16 2022-11-16 Inhibiteurs de l'usp9x

Publications (1)

Publication Number Publication Date
CA3237744A1 true CA3237744A1 (fr) 2023-05-25

Family

ID=86396480

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3237744A Pending CA3237744A1 (fr) 2021-11-16 2022-11-16 Inhibiteurs de l'usp9x

Country Status (3)

Country Link
EP (1) EP4433462A4 (fr)
CA (1) CA3237744A1 (fr)
WO (1) WO2023089601A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119113118B (zh) * 2024-09-19 2025-09-23 中南大学 USP33抑制剂在制备抗SARS-CoV-2病毒药物中的应用、抗病毒药物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004224418A1 (en) * 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
EP3852790A4 (fr) * 2018-09-19 2022-08-10 Forma Therapeutics, Inc. Inhibition de la peptidase 9x spécifique de l'ubiquitine
EP3902533A1 (fr) * 2018-12-26 2021-11-03 Forma Therapeutics, Inc. Inhibition de la peptidase 9x spécifique de l'ubiquitine

Also Published As

Publication number Publication date
EP4433462A1 (fr) 2024-09-25
WO2023089601A3 (fr) 2023-08-10
WO2023089601A2 (fr) 2023-05-25
EP4433462A4 (fr) 2025-07-16

Similar Documents

Publication Publication Date Title
JP7508578B2 (ja) 化合物及びその使用
EP3055310B1 (fr) Inhibiteurs de déubiquitinase et méthodes d'utilisation de ceux-ci
TWI864749B (zh) 化合物及其用途
JP7600396B2 (ja) 化合物及びその使用
US20240189318A1 (en) Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm
CA3254823A1 (fr) Composés hétérocycliques utiles pour moduler les complexes de baf
US20250205350A1 (en) Antibody-Drug Conjugates and Uses Thereof
CN107847497B (zh) 用于成人t细胞白血病/淋巴瘤的治疗和/或预防剂
CN114230571A (zh) 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US20250171404A1 (en) Pcna inhibitors and uses thereof
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
WO2025015149A2 (fr) Méthodes de traitement du cancer
CN121909188A (zh) 一类nsd蛋白降解剂及其用途
WO2023089601A2 (fr) Inhibiteurs d'usp9x
US11691945B2 (en) USP9X inhibitors
US12168640B2 (en) USP9X inhibitors
US20230227418A1 (en) Usp9x inhibitors
EP4687995A1 (fr) Conjugués anticorps-médicament et leurs utilisations
CA3224123A1 (fr) Inhibition de petites molecules de l'enzyme de deubiquitination josephin domain containing 1 (josd1) en tant que therapie ciblee pour des leucemies avec la janus kinase 2 (jak2) mutant
EP4537820A1 (fr) Composé et combinaisons comprenant ledit composé pour améliorer une réponse immunitaire
WO2018097999A1 (fr) Compositions et méthodes pour moduler l'activité protéase
WO2016111957A1 (fr) Composés triazole de chloroquinoline, composition et utilisations
RU2446170C2 (ru) Соединения, связывающиеся с bir доменом iap

Legal Events

Date Code Title Description
D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241220

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250211

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022